6Mon·

FDA Approves LEQEMBI® IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease

$BIIB (+0.96%) --> More sales coming?

https://investors.biogen.com/news-releases/news-release-details/fda-approves-leqembir-lecanemab-irmb-iv-maintenance-dosing

previw image

investors.biogen.comFDA Approves LEQEMBI® (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer’s Disease | Biogen

3

Join the conversation